We are live on ! Find out more
GILD icon

Gilead Sciences

1,329 hedge funds and large institutions have $139B invested in Gilead Sciences in 2014 Q3 according to their latest regulatory filings, with 127 funds opening new positions, 465 increasing their positions, 617 reducing their positions, and 51 closing their positions.

New
Increased
Maintained
Reduced
Closed

149% more first-time investments, than exits

New positions opened: 127 | Existing positions closed: 51

46% more funds holding in top 10

Funds holding in top 10: 164240 (+76)

20% more capital invested

Capital invested by funds: $115B → $139B (+$23.3B)

5% more funds holding

Funds holding: 1,2641,329 (+65)

25% less repeat investments, than reductions

Existing positions increased: 465 | Existing positions reduced: 617

38% less call options, than puts

Call options by funds: $2.56B | Put options by funds: $4.11B

Holders
1,329
Holders Change
+65
Holders Change %
+5.14%
% of All Funds
38.47%
Holding in Top 10
240
Holding in Top 10 Change
+76
Holding in Top 10 Change %
+46.34%
% of All Funds
6.95%
New
127
Increased
465
Reduced
617
Closed
51
Calls
$2.56B
Puts
$4.11B
Net Calls
-$1.55B
Net Calls Change
-$934M

GILD Hedge Fund Activity: Q3 2014 in Review

1,329 of the 3,455 institutional investors tracked by Wall St. Rank reported a position in Gilead Sciences (GILD) for Q3 2014, worth a combined $139B — up 20% from $115B a quarter earlier.

Buyers outnumbered sellers: 127 funds opened new GILD positions and 51 closed out — a net gain of 76 holders — while 465 added to existing stakes and 617 trimmed.

The largest buyer was BNP Paribas Financial Markets, adding an estimated $226M. The largest seller was Capital Research Global Investors, cutting an estimated $1.52B.

  • 1,329 institutional investors held Gilead Sciences (GILD) as of Q3 2014, up from 1,264 in Q2 2014.
  • Funds reported $139B of Gilead Sciences stock for Q3 2014, up 20% quarter-over-quarter.
  • 127 funds opened new Gilead Sciences positions in Q3 2014 and 51 closed out, a net change of +76 holders.
  • The largest Gilead Sciences buyer in Q3 2014 was BNP Paribas Financial Markets, an estimated $226M added.
  • The largest Gilead Sciences seller in Q3 2014 was Capital Research Global Investors, an estimated $1.52B sold.

Based on aggregated 13F filings for Q3 2014.